BBS Seminar Safety monitoring during the life cycle of a...
Transcript of BBS Seminar Safety monitoring during the life cycle of a...
![Page 1: BBS Seminar Safety monitoring during the life cycle of a ...bbs.ceb-institute.org/wp-content/uploads/2016/12/1_BBS-Seminar-29Nov... · Report (DSUR) •Summary of Clinical Safety](https://reader036.fdocuments.in/reader036/viewer/2022070720/5ee04c8dad6a402d666b824d/html5/thumbnails/1.jpg)
BBS Seminar
Safety monitoring during the
life cycle of a drug
Introduction
Conny Berlin
Global Head Quantitative Safety & Epidemiology
29 November 2016
![Page 2: BBS Seminar Safety monitoring during the life cycle of a ...bbs.ceb-institute.org/wp-content/uploads/2016/12/1_BBS-Seminar-29Nov... · Report (DSUR) •Summary of Clinical Safety](https://reader036.fdocuments.in/reader036/viewer/2022070720/5ee04c8dad6a402d666b824d/html5/thumbnails/2.jpg)
Increasing amount of safety data
over time
2
H-G Eichler et al, «Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval”, Clin
Pharm&Techn 2012, 91 (3), 426-437
![Page 3: BBS Seminar Safety monitoring during the life cycle of a ...bbs.ceb-institute.org/wp-content/uploads/2016/12/1_BBS-Seminar-29Nov... · Report (DSUR) •Summary of Clinical Safety](https://reader036.fdocuments.in/reader036/viewer/2022070720/5ee04c8dad6a402d666b824d/html5/thumbnails/3.jpg)
Increase in safety knowledge
• Investigator
Brochure
• Development
Safety Update
Report (DSUR)
• Summary of
Clinical Safety
(SCS)
• Labeling (Package
Insert)
• Risk Management
Plan (RMP)
• Periodic Safety
Update Report
(PSUR)
3
H-G Eichler et al, «Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval”, Clin
Pharm&Techn 2012, 91 (3), 426-437
![Page 4: BBS Seminar Safety monitoring during the life cycle of a ...bbs.ceb-institute.org/wp-content/uploads/2016/12/1_BBS-Seminar-29Nov... · Report (DSUR) •Summary of Clinical Safety](https://reader036.fdocuments.in/reader036/viewer/2022070720/5ee04c8dad6a402d666b824d/html5/thumbnails/4.jpg)
Adverse Drug Reactions Section
(FDA ADR guidance 2006)
... Exhaustive lists of every reported adverse event,
including those that are infrequent and minor, commonly
observed in the absence of drug therapy or not plausibly
related to drug therapy should be avoided.
4
![Page 5: BBS Seminar Safety monitoring during the life cycle of a ...bbs.ceb-institute.org/wp-content/uploads/2016/12/1_BBS-Seminar-29Nov... · Report (DSUR) •Summary of Clinical Safety](https://reader036.fdocuments.in/reader036/viewer/2022070720/5ee04c8dad6a402d666b824d/html5/thumbnails/5.jpg)
Informative package leaflet
5
![Page 6: BBS Seminar Safety monitoring during the life cycle of a ...bbs.ceb-institute.org/wp-content/uploads/2016/12/1_BBS-Seminar-29Nov... · Report (DSUR) •Summary of Clinical Safety](https://reader036.fdocuments.in/reader036/viewer/2022070720/5ee04c8dad6a402d666b824d/html5/thumbnails/6.jpg)
IMI PROTECT - Signal detection in
Clinical Trial Data, Spontaneous
Reports, Observational Data
6
![Page 7: BBS Seminar Safety monitoring during the life cycle of a ...bbs.ceb-institute.org/wp-content/uploads/2016/12/1_BBS-Seminar-29Nov... · Report (DSUR) •Summary of Clinical Safety](https://reader036.fdocuments.in/reader036/viewer/2022070720/5ee04c8dad6a402d666b824d/html5/thumbnails/7.jpg)
Signal detection in Clinical Trial
Data
7
![Page 8: BBS Seminar Safety monitoring during the life cycle of a ...bbs.ceb-institute.org/wp-content/uploads/2016/12/1_BBS-Seminar-29Nov... · Report (DSUR) •Summary of Clinical Safety](https://reader036.fdocuments.in/reader036/viewer/2022070720/5ee04c8dad6a402d666b824d/html5/thumbnails/8.jpg)
Safety evaluation of Clinical Trial
Data
8
![Page 9: BBS Seminar Safety monitoring during the life cycle of a ...bbs.ceb-institute.org/wp-content/uploads/2016/12/1_BBS-Seminar-29Nov... · Report (DSUR) •Summary of Clinical Safety](https://reader036.fdocuments.in/reader036/viewer/2022070720/5ee04c8dad6a402d666b824d/html5/thumbnails/9.jpg)
Today’s agenda
15:10 – 15:35 Yusuf Tanrikulu, Roche
Signal Detection - Quantitative analysis of safety data
9
16:00 – 16:25 Pritibha Singh, Novartis
ADR screening in Clinical Trials
15:35 – 16:00 Gianmario Candore, EMA
Routine signal detection at EMA
16:25 – 16:50 Soheila Aghlmandi, University Bern
Choice of prior distribution in rare-events meta-analysis
16:50 – 17:00 Marisa Bacchi, Actelion
Discussion
![Page 10: BBS Seminar Safety monitoring during the life cycle of a ...bbs.ceb-institute.org/wp-content/uploads/2016/12/1_BBS-Seminar-29Nov... · Report (DSUR) •Summary of Clinical Safety](https://reader036.fdocuments.in/reader036/viewer/2022070720/5ee04c8dad6a402d666b824d/html5/thumbnails/10.jpg)
Possible topics for future BBS
seminars
10
Signal detection in ongoing clinical trials
![Page 11: BBS Seminar Safety monitoring during the life cycle of a ...bbs.ceb-institute.org/wp-content/uploads/2016/12/1_BBS-Seminar-29Nov... · Report (DSUR) •Summary of Clinical Safety](https://reader036.fdocuments.in/reader036/viewer/2022070720/5ee04c8dad6a402d666b824d/html5/thumbnails/11.jpg)
Possible topics for future BBS
seminars
11
How to measure effectiveness of additional Risk
Minimization Measures?
![Page 12: BBS Seminar Safety monitoring during the life cycle of a ...bbs.ceb-institute.org/wp-content/uploads/2016/12/1_BBS-Seminar-29Nov... · Report (DSUR) •Summary of Clinical Safety](https://reader036.fdocuments.in/reader036/viewer/2022070720/5ee04c8dad6a402d666b824d/html5/thumbnails/12.jpg)
Possible topics for future BBS
seminars
12
Signal detection in observational data